These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27206232)

  • 21. Epilepsy in Korean patients with Angelman syndrome.
    Park SH; Yoon JR; Kim HD; Lee JS; Lee YM; Kang HC
    Korean J Pediatr; 2012 May; 55(5):171-6. PubMed ID: 22670152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic approach to neurological manifestations of Angelman syndrome.
    Ascoli M; Elia M; Gasparini S; Bonanni P; Mastroianni G; Cianci V; Neri S; Pascarella A; Santangelo D; Aguglia U; Ferlazzo E
    Expert Rev Clin Pharmacol; 2022 Jul; 15(7):843-850. PubMed ID: 35917229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epilepsy with myoclonic absences: Electroclinical characteristics in a distinctive pediatric epilepsy phenotype.
    Zanzmera P; Menon RN; Karkare K; Soni H; Jagtap S; Radhakrishnan A
    Epilepsy Behav; 2016 Nov; 64(Pt A):242-247. PubMed ID: 27770719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of topiramate in childhood generalized seizure disorders.
    Wheless JW
    J Child Neurol; 2000; 15 Suppl 1():S7-13. PubMed ID: 11218056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacotherapeutic management of seizures in patients with Angleman Syndrome.
    Samanta D
    Expert Opin Pharmacother; 2022 Sep; 23(13):1511-1522. PubMed ID: 35862628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of anticonvulsant effectiveness and safety in patients with Angelman's syndrome using an Internet questionnaire.
    Nolt DH; Mott JM; Lopez WL
    Am J Health Syst Pharm; 2003 Dec; 60(24):2583-7. PubMed ID: 14735775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Epilepsy in Angelman syndrome].
    Bobylova MY; Mukhin KY; Kuzmich GV; Glukhova LY; Pylayeva OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):100-105. PubMed ID: 35904299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aggravation of atonic seizures by rufinamide: A case report.
    Bektaş G; Çalışkan M; Aydın A; Pembegül Yıldız E; Tatlı B; Aydınlı N; Özmen M
    Brain Dev; 2016 Aug; 38(7):654-7. PubMed ID: 26906013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epilepsy treatment in adults and adolescents: Expert opinion, 2016.
    Shih JJ; Whitlock JB; Chimato N; Vargas E; Karceski SC; Frank RD
    Epilepsy Behav; 2017 Apr; 69():186-222. PubMed ID: 28237319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiepileptic drug utilisation and seizure outcome among paediatric patients in a Malaysian public hospital.
    Hasan SS; Bahari MB; Babar ZU; Ganesan V
    Singapore Med J; 2010 Jan; 51(1):21-7. PubMed ID: 20200771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy.
    Fitton A; Goa KL
    Drugs; 1995 Oct; 50(4):691-713. PubMed ID: 8536554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse effects of vigabatrin in Angelman syndrome.
    Kuenzle C; Steinlin M; Wohlrab G; Boltshauser E; Schmitt B
    Epilepsia; 1998 Nov; 39(11):1213-5. PubMed ID: 9821987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angelman syndrome in adolescence and adulthood: A retrospective chart review of 53 cases.
    Prasad A; Grocott O; Parkin K; Larson A; Thibert RL
    Am J Med Genet A; 2018 Jun; 176(6):1327-1334. PubMed ID: 29696750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability.
    Alvarez N; Besag F; Iivanainen M
    J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():1-15. PubMed ID: 10030426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Episodic tremors representing cortical myoclonus are characteristic in Angelman syndrome due to UBE3A mutations.
    Goto M; Saito Y; Honda R; Saito T; Sugai K; Matsuda Y; Miyatake C; Takeshita E; Ishiyama A; Komaki H; Nakagawa E; Sasaki M; Uto C; Kikuchi K; Motoki T; Saitoh S
    Brain Dev; 2015 Feb; 37(2):216-22. PubMed ID: 24796722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapeutic management of epilepsy in MERRF syndrome.
    Finsterer J
    Expert Opin Pharmacother; 2019 Jul; 20(10):1289-1297. PubMed ID: 31063406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefit of corticosteroid therapy in Angelman syndrome.
    Forrest KM; Young H; Dale RC; Gill DS
    J Child Neurol; 2009 Aug; 24(8):952-8. PubMed ID: 19666884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
    Montouris G; Abou-Khalil B
    Epilepsia; 2009 Sep; 50 Suppl 8():16-20. PubMed ID: 19702728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy.
    Vajda FJ; O'Brien T; Lander C; Graham J; Eadie M
    Epilepsia; 2014 Aug; 55(8):1229-34. PubMed ID: 24995555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurologic manifestations of Angelman syndrome.
    Thibert RL; Larson AM; Hsieh DT; Raby AR; Thiele EA
    Pediatr Neurol; 2013 Apr; 48(4):271-9. PubMed ID: 23498559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.